INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS) Financial Analysis

Minerva Surgical (NASDAQ:UTRS) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Minerva Surgical and INVO Fertility”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	N/A
INVO Fertility	$6.53 million	0.40	-$9.10 million	($630.30)	0.00

INVO Fertility has lower revenue, but higher earnings than Minerva Surgical. INVO Fertility is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Minerva Surgical and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Surgical	N/A	N/A	N/A
INVO Fertility	-417.02%	N/A	-92.42%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Minerva Surgical and INVO Fertility, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Surgical	0	0	0	0	0.00
INVO Fertility	1	0	0	0	1.00

Given Minerva Surgical’s higher probable upside, research analysts plainly believe Minerva Surgical is more favorable than INVO Fertility.

Institutional and Insider Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by company insiders. Comparatively, 0.7% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Minerva Surgical has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.

Summary

Minerva Surgical beats INVO Fertility on 7 of the 10 factors compared between the two stocks.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.